Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloVax in Recurrent/Metastatic SCCHN
NCT01998542Phase 2Completed
- Sponsor
- Mirror Biologics, Inc.
- Start
- Jan 2016
- Primary completion
- Jun 2017
- Modality
- Cell Therapies, Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of AlloVax in squamous cell carcinoma of the head and neck (HNSCC), sponsored by Mirror Biologics, Inc.. Started Jan 2016; status: completed.
02
Drugs
AlloVax
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01998542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01998542.